Organon & Co OGN 深 滬
已收盤 11-06 16:00:00 美东时间
13.87
+0.080
+0.58%
華盛通- 最 高13.87
- 今 開13.80
- 成交量 394.72万股
- 最 低 13.78
- 昨 收 13.79
- 總市值 36.43亿
- 52周最高 13.88
- 市盈率 靜 19.34
- 換手率 0.00%
- 52周最低 5.65
- 委 比 89.63%
- 總股本 2.63亿
- 歷史最高 35.995
- 量 比 1.40
- 振 幅 0.65%
- 歷史最低 5.65
- 每 手 1
- 風險率 3.13%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Entera Announces Third Quarter 2026 Financial Results and Business Updates
Entera Bio Ltd. reported financial results and updates for Q3 2026, highlighting advancements in its EB613 Phase 3 osteoporosis study, expected to begin late 2026. The company expanded its clinical leadership team with key appointments and presented positive EB613 data at ASBMR 2026, showing enhanced bone formation and BMD gains. EB612, in development for hypoparathyroidism, is progressing with IND-enabling studies. Cash reserves of $265.9M suppo...
11-06 21:15
财报速睇 | Organon & Co 2026财年Q3归母净利润1.64亿美元，同比增长2.5%
华盛资讯10月30日讯，Organon & Co公布2026财年Q3业绩，公司Q3归母净利润1.64亿美元，同比增长2.5%。
10-30 20:30
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
Entera Bio Ltd. announced the appointment of Juan Camilo Arjona Ferreira, M.D., as a Board member, effective December 1, 2026. Dr. Arjona Ferreira, a seasoned clinical leader with over 20 years of experience in women’s health and regulatory affairs, succeeds Haya Taitel. His expertise aligns with Entera’s focus on developing oral peptide therapies, particularly for osteoporosis and hypoparathyroidism. Dr. Arjona Ferreira currently leads Organon’s...
10-27 12:00
葛兰素史克、Inovio、Agios扎堆候审，美股创新药迎FDA审批窗口
FDA 未来两周将密集裁决多款新药：GSK 乙肝功能性治愈疗法、Inovio 罕见病疗法、Agios 镰状细胞病新药及太阳制药扩适应症申请。
10-19 23:40
葛兰素史克(GSK.US)、Inovio(INO.US)、Agios(AGIO.US)扎堆候审，美股创新药迎FDA审批窗口
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-19 19:25
Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Women’s Health will present interim results from an ongoing Phase 3 study evaluating MIUDELLA®, a hormone-free, copper intrauterine devi...
10-16 19:34
Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis
Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric patients 2 years of age and older.
09-28 20:09
DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List
Daré Bioscience CEO Sabrina Martucci Johnson has been named to Forbes' 2026 "50 Over 50: Innovation" list, recognizing her leadership in advancing women's health innovation. Daré Bioscience, founded in 2015, is dedicated to addressing unmet needs in women's health through a multi-product strategy spanning contraception, sexual health, menopause, and infectious disease. The company's portfolio includes FDA-approved products, Phase 3 clinical trial...
08-18 13:02
This House of Representative Just Sold Up To $30K In Organon Stock
A report on August 12, 2026 shows that Representative Kevin Hern from Oklahoma sale stock in Organon (NYSE:OGN), valued between $2,002 and $30,000. According to the August filing, the transaction occurred on August 5, 2026. At the time of writing, Organon shares are trading up 0.33% at $13.7. What R...
08-13 23:01
Eikon Therapeutics Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
Eikon Therapeutics reported Q2 2026 financial results with $531.2 million in cash and presented seven abstracts at ESMO 2026, highlighting clinical progress across its oncology portfolio, including EIK1001, EIK1003, EIK1004, and EIK1005. The company also appointed Ma. Fatima Francisco to its Board of Directors and announced key upcoming milestones for its pipeline.
08-13 20:02
